FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

32 letters match. Newest first.

  1. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk
  2. Fresenius Medical Care AG & Co. KGaA

    Fresenius Medical Care's Ogden, Utah plant failed to investigate leaking peritoneal dialysis bags, leading to a 2026 recall.

    High risk
  3. Excelvision - Fareva

    FDA warned Excelvision-Fareva after a 2026 inspection found inadequate contamination investigations and aseptic failures for sterile drugs.

    High risk
  4. Happiest Baby, Inc.

    FDA says Happiest Baby marketed unapproved SNOO sleep sacks and hospital bundle and mishandled complaints.

    High risk
  5. CareFusion 213, LLC

    FDA warns CareFusion 213 over inadequate investigations and contamination controls at its El Paso sterile drug plant.

    High risk
  6. Cohance Lifesciences Limited

    Cohance Lifesciences, a finished-drug maker, was cited for inadequate investigations and dirty shared equipment that caused cross-contamination.

    High risk
  7. Unomedical Device S.A. de C.V.

    FDA warns Unomedical over insulin infusion sets with unvalidated leak tests and unreported serious injuries.

    High risk
  8. Darmerica, LLC

    FDA warns Darmerica over manufacturing-quality violations and mislabeled drug ingredients, including retatrutide.

    High risk
  9. Envoy Medical Inc.

    Envoy Medical in Saint Paul, MN was cited for quality system failures in making its Esteem II Implantable Hearing System, including slow complaint investigations and missed cleanroom contamination risks.

    High risk
  10. Janssen Vaccines Corp., A Johnson & Johnson Company

    FDA warned Janssen Vaccines over inadequate investigations of stopper complaints and missed regulatory notifications for its injection drug.

    Medium
  11. Reset Technology Corporation

    FDA warns Reset Technology about missing validation and complaint handling for ResetSmile dental devices.

    High risk
  12. Excelvision Fareva

    Excelvision Fareva, a sterile drug manufacturer, was cited for inadequate mold/black-speck complaint investigations and aseptic contamination controls.

    High risk
  13. Noah Medical Corporation

    FDA warns Noah Medical of San Jose, CA over quality system failures and missed injury reports for its Galaxy bronchoscopes.

    High risk
  14. Shree Jaya Laboratories PVT. LTD.

    FDA warned Shree Jaya Laboratories after an inspection found CGMP deviations in API and intermediate manufacturing, including dirty equipment and torn batch records.

    High risk
  15. Indoco Remedies Limited

    FDA warned Indoco Remedies over manufacturing quality failures at its Goa plant, including unreliable microbial testing and aseptic processing deficiencies.

    High risk
  16. Sombra Cosmetics, Inc.

    FDA warned Sombra Cosmetics of OTC drug CGMP violations, including inadequate water controls and component testing.

    High risk
  17. Brands International Corporation

    Brands International, a Canadian drug manufacturer, limited an FDA inspection and had manufacturing quality violations including mold contamination.

    High risk
  18. Azurity Pharmaceuticals, Inc.

    FDA warned Azurity Pharmaceuticals over unapproved FIRST drug kits and manufacturing quality failures at its Wilmington, MA plant.

    High risk
  19. Globus Medical, Inc.

    FDA warns Globus Medical over Excelsius GPS robot-related misplaced screw complaints and late or missing device reports.

    High risk
  20. Trexo Robotics Holdings Inc.

    FDA warns Trexo Robotics over unapproved robotic gait-training legs for children and design-control gaps at its Canadian plant.

    High risk
  21. Westwood Laboratories LLC

    FDA warned Westwood Laboratories after an inspection found inadequate investigations, raw material testing, lab controls, and water/cleaning controls for OTC drugs.

    High risk
  22. Sichuan Deebio Pharmaceutical Co. Ltd.

    FDA warns Sichuan Deebio Pharmaceutical over API manufacturing and data-integrity failures.

    High risk
  23. Olympus Medical Systems Corp.

    FDA warned Olympus Medical Systems about endoscope accessories for quality-system, complaint, packaging-seal, and reporting failures.

    High risk
  24. MD Pharmaceutical Supply, LLC

    FDA warns MD Pharmaceutical Supply over API repackaging failures, including redistributing a returned lot and uncontrolled cross-contamination risks.

    High risk
  25. Nutritional Laboratories International, Inc. DBA Elite One Source Nutritional Services, Inc.

    FDA warns Nutritional Laboratories International over CGMP violations and misbranded dietary supplement labels found after 2021 inspection.

    Medium
  26. Zyno Medical LLC

    FDA warns Zyno Medical over infusion pump and administration set quality violations and unapproved set changes.

    High risk
  27. Jost Chemical Co.

    Jost Chemical Co. made active drug ingredients under CGMP deviations, including mold contamination and inadequate investigations.

    High risk
  28. Bi-Coastal Pharma International

    FDA warned Bi-Coastal Pharma International about adulterated drugs due to poor complaint handling, quality-unit oversight, batch release, and training.

    High risk
  29. Aire-Master of America, Inc.

    FDA cites Aire-Master of America for CGMP failures and unapproved, misbranded hand sanitizers made at its Missouri plant.

    High risk
  30. Vi-Jon, LLC

    FDA cited Vi-Jon for manufacturing-rule violations after finding microbial water contamination, leaks, weak investigations, and data-integrity failures in OTC drugs and cosmetics.

    High risk
  31. DSAART, LLC. dba Alpha Aesthetics

    FDA warned Alpha Aesthetics after inspection found unvalidated sterilization and manufacturing, poor complaint handling, and missed injury reports for silicone implants.

    High risk
  32. DeVilbiss Healthcare LLC

    FDA cites DeVilbiss over oxygen concentrator overheating and late medical device reports.

    High risk